Enrico Montefusco

Sapienza University of Rome — Italy

Medicine · Health Sciences

30h-index3.0kcitations145works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(94), Chronic Lymphocytic Leukemia Research(57), Acute Myeloid Leukemia Research(40), Eosinophilic Disorders and Syndromes(38), Myeloproliferative Neoplasms: Diagnosis and Treatment(31)

Publications143 total

Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells
PubMed·2022· 6 citedOpen Access
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols
Acta Oncologica·2021· 7 citedOpen Access
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols
Figshare·2021Open Access
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”
European Journal Of Haematology·2020· 14 cited
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
Blood Advances·2019· 89 citedOpen Access
Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols
Blood·2019· 1 cited
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline
Annals of Hematology·2019· 19 cited
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Leukemia Research·2018· 9 cited
High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia
Thrombosis Research·2017· 13 cited
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia
Cancer Medicine·2017· 10 citedOpen Access
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome
British Journal of Haematology·2017· 11 citedOpen Access
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
2017
Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN)
Blood·2016· 1 cited
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome
Oncotarget·2016· 35 citedOpen Access
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients
American Journal of Hematology·2016· 38 citedOpen Access
CHRONIC MYELOID LEUKEMIA WITH EXTREME THROMBOCYTOCIS AT THE DIAGNOSIS: A NEW SUBSET
CINECA IRIS Institutial research information system (University of Pisa)·2016· 2 citedOpen Access
Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response
Blood·2015
Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis
Blood·2015· 2 cited
Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline
Blood·2015
Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms
Blood·2015
page 1 of 8Next →

Frequent Co-authors

Massimo Breccia(18), Giuliana Alimena(17), Roberto Latagliata(14), Antonio Spadea(12), Franco Mandelli(12), Gianantonio Rosti(11), Michele Baccarani(10), Mario Tiribelli(10), Michele Cedrone(10), Marco Mancini(9), Patrizia Pregno(8), Giuseppe Saglio(7), Fausto Castagnetti(7), Elisabetta Abruzzese(7), Mario Annunziata(7), Francesco Cavazzini(7), Antonella Gozzini(7), Fabio Stagno(7), Nicoletta Testoni(6), Gianni Binotto(6)